



Bachem and BioSpring agree to collaborate on oligonucleotide-peptide conjugates for R&D

Bubendorf/Basel, Switzerland and Frankfurt, Germany March 2, 2012 – Bachem (SIX: BANB) and BioSpring GmbH today announced that the two companies have concluded an agreement to cooperate on the manufacture of oligonucleotide-peptide conjugates involved in R&D projects. The required expertise for both oligonucleotide and peptide chemistry are thus brought together for a future collaboration by two manufacturers experienced in their fields.

Dr. Anne-Kathrin Stoller, Vice President Marketing & Sales of Bachem AG, comments: “There is an increasing number of examples of new drug development candidates now reaching clinical trials where both types of chemistry are involved. Bachem is delighted to partner with a successful and dynamic company such as BioSpring to offer pharmaceutical and biotech customers an excellent combination of synthetic skills “.

“We are particularly enthusiastic regarding this partnership with Bachem” adds Dr. Sylvia Wojczewski, CEO of BioSpring, who continues: “Both the geographic proximity and the respective technical expertise will help making this partnership productive for both our organizations.”

About Bachem

Bachem is an independent, technology-based, public biochemicals company providing full service to the pharma and biotech industry. Bachem is specialized in the process development and the manufacturing of peptides and complex organic molecules as active pharmaceutical ingredients (APIs), as well as innovative biochemicals for research purposes. With headquarters in Bubendorf, Switzerland, and affiliates in Europe and the US, Bachem works on a global scale and holds a leading position in the field of peptides.

About BioSpring

BioSpring is an independent cGMP certified company providing synthetic oligonucleotides for therapeutic, diagnostic and research applications. The company’s manufacturing capabilities cover the whole range from small scale for initial research up to commercial quantities. BioSpring provides a large range of services for analytical development, quality control and in depth characterization of oligonucleotide based drug substances and drug products for the pharmaceutical industry. The company is headquartered in Frankfurt, Germany.

Contact:

For further questions, please visit our websites or contact the person below.

Bachem Holding AG
Stephan Schindler, CFO
Tel.: +41 61 935 2333
Fax: +41 61 935 2324
ir@bachem.com
www.bachem.com

BioSpring
Dr. Sylvia Wojczewski, CEO
Tel.: +49 69 4089 4471
info@biospring.de
www.biospring.de